References
- van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084–98.
- van Eijk RPA, Kliest T, van den Berg LH. Current trends in the clinical trial landscape for amyotrophic lateral sclerosis. Curr Opin Neurol. 2020;33:655–61.
- Food Drug Administration Center for Drugs Evaluation Research. Guidance for industry: amyotrophic lateral sclerosis: developing drugs for treatment 2019 [Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/amyotrophic-lateral-sclerosis-developing-drugs-treatment-guidance-industry.
- European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis (ALS) 2016 [Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-amyotrophic-lateral-sclerosis_en.pdf.
- Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13–21.
- Gordon PH, Miller RG, Moore DH. ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(Suppl 1):90–3.
- Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 2006;66:265–7.
- Bakker LA, Schroder CD, Tan HHG, Vugts S, van Eijk RPA, van Es MA, et al. Development and assessment of the inter-rater and intra-rater reproducibility of a self-administration version of the ALSFRS-R. J Neurol Neurosurg Psychiatry. 2020;91:75–81.
- Franchignoni F, Mandrioli J, Giordano A, Ferro S, Group E. A further Rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:331–7.
- Bedlack RS, Vaughan T, Wicks P, Heywood J, Sinani E, Selsov R, et al. How common are ALS plateaus and reversals? Neurology 2016;86:808–12.
- Harrison D, Mehta P, van Es MA, Stommel E, Drory VE, Nefussy B, et al. "ALS reversals": demographics, disease characteristics, treatments, and co-morbidities. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:495–9.
- Vasta R, D'Ovidio F, Canosa A, Manera U, Torrieri MC, Grassano M, et al. Plateaus in amyotrophic lateral sclerosis progression: results from a population-based cohort. Eur J Neurol. 2020;27:1397–404.
- Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12:1059–67.
- Berry JD, Miller R, Moore DH, Cudkowicz ME, van den Berg LH, Kerr DA, et al. The combined assessment of function and survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:162–8.
- Meininger V, Genge A, van den Berg LH, Robberecht W, Ludolph A, Chio A, et al. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16:208–16.
- Northeast Amyotrophic Lateral Sclerosis Consortium. [Available from: https://www.neals.org/.
- Dombernowsky T, Haedersdal M, Lassen U, Thomsen SF. Criteria for site selection in industry-sponsored clinical trials: a survey among decision-makers in biopharmaceutical companies and clinical research organizations. Trials 2019;20:708.
- Walker R, Morris DW, Greer TL, Trivedi MH. Research staff training in a multisite randomized clinical trial: methods and recommendations from the stimulant reduction intervention using dosed exercise (STRIDE) trial. Addict Res Theory. 2014;22:407–15.
- van Eijk RPA, Kliest T, McDermott CJ, Roes KCB, Van Damme P, Chio A, et al. TRICALS: creating a highway toward a cure. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:496–501.
- Motor Neurone Disease group Australia [Available from: https://www.sydney.edu.au/brain-mind/our-research/forefront-ageing-and-neurodegeneration/motor-neurone-disease.html.
- Gehring M, Taylor RS, Mellody M, Casteels B, Piazzi A, Gensini G, et al. Factors influencing clinical trial site selection in Europe: the survey of attitudes towards trial sites in Europe (the SAT-EU Study). BMJ Open. 2013;3:e002957.
- Sutherland AE, Stickland J, Wee B. Can video consultations replace face-to-face interviews? Palliative medicine and the Covid-19 pandemic: rapid review. BMJ Support Palliat Care. 2020;10:271–5.